Probiotics do not cure bacterial vaginosis. In the US, BV is diagnosed by a clinician and treated with prescription antibiotics — metronidazole or clindamycin. What probiotics have evidence for is the harder second problem: keeping BV from coming straight back. Pooled trial data supports them as an add-on after antibiotics, not as a replacement for them.
The Short Answer, Stated Plainly
Two different questions get blurred together in almost every article on this topic, so separate them first.
"Can a probiotic clear an active case of BV?" The honest answer is no, and the trial data says so directly. A 2019 meta-analysis in the European Journal of Pharmacology pooled 13 randomised controlled trials covering 1,258 women. Where probiotics were tested against antibiotics as a standalone treatment, the pooled risk ratio was 1.03 (95% CI 0.38–2.81, p = 0.95) — no meaningful difference, on only two trials, with confidence intervals wide enough to drive a truck through (Li et al., 2019).
"Can a probiotic help after antibiotics?" Here the picture changes. In the same meta-analysis, nine trials compared antibiotics plus probiotics against antibiotics alone and found a modest advantage: RR 1.28 (95% CI 1.05–1.56, p = 0.02). The authors' own summary is worth quoting rather than dressing up — probiotics "may have a positive effect on the treatment of BV, but there is a lack of strong evidence."
That is the state of the science in 2026. Useful, real, and considerably smaller than the marketing around it.
BV Is Common in the US — and It Comes Back
Bacterial vaginosis is not a rare or exotic problem. A systematic review and meta-analysis in Sexually Transmitted Diseases put general-population prevalence in North America at 27% of reproductive-age women, with significant variation by group: 33% among Black women, 31% among Hispanic women, 23% among white women and 11% among Asian women (Peebles et al., 2019).
The recurrence figure is the one that explains why this market exists at all. In a prospective cohort published in the Journal of Infectious Diseases, women treated with a standard seven-day course of oral metronidazole were followed for a year. By 12 months, 58% had a recurrence of BV by Nugent score, and 69% had a recurrence of abnormal vaginal flora (Bradshaw et al., 2006). The authors' conclusion was blunt: current recommended treatment is not preventing recurrence in the majority of women.
So the antibiotic works and then, more often than not, the problem returns. That gap is the only place a supplement has a legitimate role.
Why the Vaginal Microbiome Is Its Own Ecosystem
A healthy vaginal microbiome is not simply "more good bacteria." Sequencing work on 396 asymptomatic North American women, published in PNAS, found the community clusters into five distinct types. Four are dominated by a single Lactobacillus species — L. crispatus, L. iners, L. gasseri or L. jensenii — and the fifth has few lactic-acid bacteria and a higher proportion of strict anaerobes (Ravel et al., 2011). Vaginal pH also differed measurably between ethnic groups in that cohort.
This matters for reading any probiotic label. The species that actually dominate a healthy vaginal community are a short, specific list. Most oral probiotic strains sold for feminine health — including the two with the best BV evidence — are not on it. They are gut and urogenital travellers chosen because they survive the trip and can reach the vaginal tract, not because they are the resident species.
Contender 1: Antibiotics, the Only Actual Treatment
Prescription metronidazole or clindamycin is the standard of care for a confirmed BV diagnosis in the US, and nothing on a supplement shelf substitutes for it. BV also carries associations with adverse outcomes that make self-treating a poor idea, which is why diagnosis belongs with a clinician who can rule out the conditions that look similar.
If you have symptoms — a thin grey or white discharge, a distinct odour that is stronger after sex, itching or burning — the first step is an appointment, not an order confirmation.
Contender 2: Vaginal Probiotics, Where the Strongest Single Trial Sits
The most rigorous probiotic result in this field is LACTIN-V, published in the New England Journal of Medicine. Researchers randomised 228 women aged 18–45 who had completed a course of vaginal metronidazole gel, in a 2:1 ratio, to Lactobacillus crispatus CTV-05 or placebo for 11 weeks. Recurrence by week 12 was 30% in the LACTIN-V group versus 45% on placebo (Cohen et al., 2020).
Read the design carefully, because two details get dropped constantly. First, LACTIN-V was administered vaginally, through an applicator — not swallowed. Second, every participant had already completed antibiotic treatment before the probiotic started. The trial tested prevention of recurrence, not cure.
The same route pattern shows up elsewhere. A randomised, double-blind, placebo-controlled trial of 277 women found that 250 mg ascorbic acid vaginal tablets, used once daily for six days, produced a cure rate of 55.3% against 25.7% for placebo in the intention-to-treat population (Petersen et al., 2011). That is a vitamin C result — and it is a vitamin C result for a tablet placed in the vagina, which tells you nothing about swallowing vitamin C.
Contender 3: Oral Probiotics, What the Evidence Actually Supports
Oral strains are not without data. Two trials carry most of the weight.
In a FEMS Immunology & Medical Microbiology trial, 64 healthy women took daily oral capsules of L. rhamnosus GR-1 and RC-14 for 60 days. Among women who started with asymptomatic BV-pattern flora, 37% were restored to normal lactobacilli-dominated flora versus 13% on placebo (p = 0.02), with significant increases in vaginal lactobacilli at days 28 and 60 (Reid et al., 2003). A naming note that trips people up: that paper calls RC-14 L. fermentum; the same strain was later reclassified as L. reuteri, which is how it appears on labels today.
The stronger result came in Microbes and Infection. Researchers enrolled 125 premenopausal women with diagnosed BV, treated all of them with oral metronidazole twice daily for seven days, and randomised them to oral GR-1 and RC-14 or placebo for 30 days. At day-30 follow-up, 88% of the antibiotic-plus-probiotic group met the cure definition versus 40% of the antibiotic-plus-placebo group (Anukam et al., 2006).
That 88% figure is quoted everywhere. Two caveats belong beside it every time: the trial was conducted in a Nigerian cohort and its authors framed the finding as applying to the women studied, and the antibiotic was doing the clearing in both arms.
And the counterweight, which most pages selling probiotics never mention: a 2020 randomised controlled trial in Nutrients gave the same oral GR-1 and RC-14 combination twice daily for 12 weeks to 86 low-risk pregnant women with an intermediate or BV Nugent score. The Nugent score returned to normal in 30% of women — in both the probiotic and the placebo groups — with no difference in bacterial diversity at 13, 28 or 35 weeks (Yang et al., 2020). Same strains, different population, null result.
The Route Problem — and the Honest Rebuttal to It
Line up the landmark trials and a pattern jumps out. The strongest recurrence-prevention result used a vaginal applicator. The vitamin C result used a vaginal tablet. The oral results are real but smaller, and one well-run oral trial found nothing at all.
It would be easy to end there and declare that route is everything. The pooled evidence does not support that conclusion, and saying so is the difference between an argument and a sales pitch.
A 2022 systematic review and meta-analysis in Frontiers in Nutrition examined 10 studies covering 1,234 participants, all of which gave probiotics after a standard antibiotic regimen and reassessed BV status at least one menstrual cycle later. Probiotics reduced recurrence risk by 45% — 14.8% versus 25.5%, RR 0.55 (95% CI 0.33–0.91, p = 0.03) — and the result held on sensitivity analysis after removing high-risk-of-bias studies. Critically, the authors' meta-regression tested whether route of administration predicted outcome and found that it did not (p = 0.67 for vaginal, p = 0.44 for oral). Total dose, days of administration and number of species were likewise unrelated to the result (Chieng et al., 2022).
So the fair reading is this: the single most impressive trial used a vaginal strain delivered vaginally, and you should not assume that specific result transfers to a gummy — but across the whole pooled literature, oral delivery has not been shown to be the weaker route. Anyone claiming certainty in either direction is ahead of the evidence.
How the Three Options Compare
| Prescription antibiotics | Vaginal probiotic (e.g. L. crispatus CTV-05) | Oral probiotic gummy | |
|---|---|---|---|
| Clears an active BV diagnosis | Yes — standard of care | No; trials start after antibiotics | No |
| Best evidence | Established clinical guidelines | 30% vs 45% recurrence at wk 12, n=228 (NEJM) | RR 1.28 as antibiotic add-on, 13 RCTs, n=1,258 |
| Contradicting evidence | Recurrence 58% at 12 months | Phase 2b, single trial | Null result in 86 pregnant women (Nutrients 2020) |
| Route | Oral or vaginal, prescription | Vaginal applicator | Swallowed daily |
| Availability in the US | Prescription only | Not sold as a consumer supplement | Retail, no prescription |
| Typical daily cost | Course-based, varies by insurance | Not applicable | About $1.37/day at $40.99 |
| Realistic role | Treatment | Recurrence prevention | Recurrence prevention, adjunct only |
OUR VERDICT
If you have symptoms right now, see a clinician and take the antibiotic — a gummy is not an alternative and we will not pretend otherwise. If you have finished a course and BV keeps returning, a daily oral probiotic is a reasonable, low-risk addition with modest pooled evidence behind it.
What Is Actually in FloraFresh — and What We Cannot Tell You
FloraFresh Vaginal Probiotics Gummies sells for $40.99. The label states 15 billion CFU per serving from four Lactobacillus species — rhamnosus, reuteri, salivarius and gasseri — alongside XOS prebiotics, D-mannose and vitamin C. The directions say two gummies daily with water, best with meals, and the pouch front reads 60 gummies, so one pouch is 30 days at the label's own serving size. Across the FloraFresh range, prices run from $24.50 for a single-bottle add-on to $110.70 for the six-month reserve.
Two of those four species — L. rhamnosus and L. reuteri — are the ones carrying the oral BV evidence above. L. gasseri is one of the four species that dominates a healthy vaginal community in the Ravel data. That is a sensible selection, and it is worth saying so.
Now the parts our own listing does not answer, because you deserve them before you spend $40.99:
- The label names species, not strains. Every trial cited on this page tested specific strain designations — GR-1, RC-14, CTV-05. Strain is not a detail; two strains of the same species can behave completely differently. Our listing does not publish the strain codes for its four species, so nobody can verify from the label alone that they are the studied ones.
- There is no per-strain CFU breakdown. 15 billion CFU is a total across four species. The split between them is not published.
- The D-mannose, XOS and vitamin C amounts are not stated. This matters for reading across from other research. The D-mannose trial that gets cited in this category used 2 g daily and measured recurrent urinary tract infection, not BV — 14.6% recurrence versus 60.8% with no prophylaxis in 308 women (Kranjčec et al., 2014). That is a different condition and a dose we cannot confirm is matched here.
- There is no photographed Supplement Facts panel in the listing images, so the figures above come from the written description and the pouch front.
If any of that is a dealbreaker for you, it should be. Email support@wellnessnest.co and ask for the strain designations before you buy — that is a fair question and we would rather you ask it than assume.
See the full FloraFresh ingredient list →
You can browse the rest of the women's range in women's essentials, and FloraFresh is also a listed member of best sellers and the wellness stack.
When to Stop and Call a Clinician
A supplement is a maintenance decision. These are not:
- Symptoms that are new, worsening, or came with a fever or pelvic pain
- Any discharge with blood in it
- Symptoms during pregnancy — BV in pregnancy is managed by an obstetric provider, and the Nutrients trial above found no probiotic benefit in that group
- Symptoms that have not improved after a completed antibiotic course
- Anything you would otherwise self-diagnose from a search result — BV, yeast infection and trichomoniasis have overlapping symptoms and different treatments
Do not start a new supplement without asking your clinician first if you are pregnant, nursing, under 18, immunocompromised, or taking daily prescription medicine.
Frequently Asked Questions
Do probiotics cure bacterial vaginosis?
No. Across 13 randomised trials with 1,258 participants, probiotics tested against antibiotics as a standalone treatment showed no significant difference and rested on only two studies. Antibiotics prescribed by a clinician clear BV; probiotics have evidence as an add-on afterwards to reduce recurrence.
How long do probiotics take to work for BV recurrence?
The trials that found a benefit ran for weeks, not days. LACTIN-V dosed for 11 weeks with follow-up to week 24, the Anukam trial ran 30 days, and the Reid trial ran 60 days. The 2022 meta-analysis only counted outcomes reassessed at least one full menstrual cycle after treatment. Our own longer explainer on how long vaginal probiotics take to work covers the timeline in detail.
Does it matter whether a probiotic is oral or vaginal?
For the single strongest trial, yes — LACTIN-V was delivered vaginally and its result should not be assumed to transfer to a swallowed product. Across the pooled literature, though, a 2022 meta-regression found route of administration was not associated with recurrence outcomes. Both statements are true and they answer slightly different questions.
Which strains have the best evidence for BV?
L. crispatus CTV-05 has the strongest single trial, delivered vaginally. For oral use, L. rhamnosus GR-1 with L. reuteri RC-14 carries the most data. Note these are strain codes, not just species names. We cover the species-level picture in which vaginal probiotic strains actually work.
Are there side effects to taking a daily vaginal probiotic?
The Reid trial reported no adverse effects across 64 women over 60 days. Mild digestive changes in the first days are the common report for oral probiotics generally. Our guide to vaginal probiotic side effects separates what is normal from what should make you stop.
Where can I buy probiotics for feminine health in the US?
FloraFresh ships nationwide from wellnessnest.co at $40.99 for a 30-day pouch, with multi-month options from $24.50 to $110.70. It is sold as a dietary supplement under US structure/function labelling, which means it is not intended to diagnose, treat, cure or prevent any disease — including BV.
About the Author
Dr. Marcus Hale — Dr. Marcus Hale is the resident health researcher behind Wellness Nest's editorial team, translating peer-reviewed sports-nutrition and longevity research into practical daily guidance for US readers.
